Quick navigation menu :

  1. Go to the content
  2. Go to main section’s menu
  3. Go to Search tool
  4. Go to language menu
  5. Go to Help menu
  6. Go to the list of keyboard shortcuts
Go to the Sanofi corporate website  

Content :

Oligonucleotides & Peptides

Expertise available from 1center of excellence:

  • Frankfurt (Germany): Our “TIDES” Platform (Oligonucleotides & Peptides) is embedded in a unique state-of-the-art infrastructure on one of the largest industrial chemistry & biotechnology sites.

CEPiA offers customized services (manufacturing and analytical) from clinical phase to submission and launch (grams scale up to kilograms quantities), including regulatory support, as well as commercial supplies.

cGMP API manufacturing can be combined with Drug Product and Devices technologies. Our facilities are regularly inspected by Health Authorities, including FDA, EMA and PMDA. One of our current development is the oligonucleotide-peptide conjugation.


Peptide production and development:

  • Liquid phase peptide synthesis and synthesis of intermediates (50 L – 600 L)
  • Solid phase peptide synthesis (10 L - 280 L)
Peptide production and development


Through Sanofi’s 25 years experience in the field of oligonucleotides, CEPiA can provide different classes of Oligonucleotides such as DNA, 2’-O-Modified, phosphorothioate derivatives.

Oligonucleotide production and development